Marshall Wace LLP lifted its stake in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) by 87.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 5,155,402 shares of the company's stock after purchasing an additional 2,410,420 shares during the quarter. Marshall Wace LLP owned about 0.46% of Teva Pharmaceutical Industries worth $113,625,000 at the end of the most recent quarter.
Other large investors have also modified their holdings of the company. FMR LLC boosted its position in shares of Teva Pharmaceutical Industries by 30.7% during the 4th quarter. FMR LLC now owns 81,983,231 shares of the company's stock worth $1,806,910,000 after purchasing an additional 19,242,468 shares in the last quarter. Clal Insurance Enterprises Holdings Ltd boosted its holdings in Teva Pharmaceutical Industries by 12.8% during the fourth quarter. Clal Insurance Enterprises Holdings Ltd now owns 38,962,773 shares of the company's stock worth $859,935,000 after buying an additional 4,418,961 shares in the last quarter. Todd Asset Management LLC acquired a new position in Teva Pharmaceutical Industries during the fourth quarter worth about $58,243,000. Raymond James Financial Inc. purchased a new position in Teva Pharmaceutical Industries in the fourth quarter valued at about $38,914,000. Finally, Norges Bank acquired a new stake in shares of Teva Pharmaceutical Industries during the 4th quarter valued at approximately $38,550,000. Hedge funds and other institutional investors own 54.05% of the company's stock.
Teva Pharmaceutical Industries Stock Down 3.0 %
Shares of NYSE TEVA traded down $0.41 on Monday, hitting $13.24. The company had a trading volume of 9,427,743 shares, compared to its average volume of 9,902,354. The company has a quick ratio of 0.75, a current ratio of 0.98 and a debt-to-equity ratio of 2.97. Teva Pharmaceutical Industries Limited has a 12-month low of $12.47 and a 12-month high of $22.80. The firm has a market capitalization of $15.01 billion, a P/E ratio of -9.13, a PEG ratio of 1.44 and a beta of 0.72. The business has a 50 day moving average of $15.45 and a two-hundred day moving average of $17.67.
Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last posted its quarterly earnings data on Wednesday, January 29th. The company reported $0.70 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.69 by $0.01. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%. As a group, equities research analysts forecast that Teva Pharmaceutical Industries Limited will post 2.5 earnings per share for the current fiscal year.
Analyst Upgrades and Downgrades
Several equities analysts recently issued reports on the company. Piper Sandler lifted their price objective on Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the stock an "overweight" rating in a report on Friday, January 17th. UBS Group decreased their target price on shares of Teva Pharmaceutical Industries from $30.00 to $27.00 and set a "buy" rating on the stock in a research report on Thursday, January 30th. StockNews.com downgraded Teva Pharmaceutical Industries from a "buy" rating to a "hold" rating in a report on Monday, April 14th. Barclays cut their price objective on shares of Teva Pharmaceutical Industries from $28.00 to $26.00 and set an "overweight" rating on the stock in a report on Thursday, January 30th. Finally, Bank of America lowered their price target on Teva Pharmaceutical Industries from $23.00 to $20.00 and set a "buy" rating for the company in a research report on Thursday, March 6th. Two equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company's stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $23.43.
View Our Latest Report on TEVA
About Teva Pharmaceutical Industries
(
Free Report)
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.
Featured Stories
Before you consider Teva Pharmaceutical Industries, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Teva Pharmaceutical Industries wasn't on the list.
While Teva Pharmaceutical Industries currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
